1) Review the latest evidence-based multidisciplinary strategies and nuances of the multiple available approaches of total neoadjuvant therapy in rectal cancer, including management considerations for patients who achieve a complete radiographic response and want to consider omitting surgery.
2) Consider the evolving role of ctDNA in colorectal cancer and appropriate applications based on available data.
3) Discuss treatment options for rare mixed neuroendocrine non-neuroendocrine neoplasms, specifically incorporating the advanced treatment paradigms of targeted therapy and sequencing as applicable to adenocarcinomas and neuroendocrine tumors of the colon.
09/28/2021 - 7:00am to 8:00am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Kiran Turaga MD, MPH, Benjamin Shogan MD, Blasé Polite MD